RemeGen Co., Ltd.
RemeGen Co., Ltd. (REGMF) Financial Performance & Income Statement Overview
Analyze RemeGen Co., Ltd. (REGMF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
RemeGen Co., Ltd. (REGMF) Income Statement & Financial Overview
Explore comprehensive income reports for RemeGen Co., Ltd. REGMF, broken down by year and quarter.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $522.30M | $503.89M | $467.12M | $411.32M |
| Cost of Revenue | $88.03M | $101.97M | $74.004M | $96.38M |
| Gross Profit | $434.27M | $352.26M | $393.11M | $314.94M |
| Gross Profit Ratio | $0.83 | $0.70 | $0.84 | $0.77 |
| R&D Expenses | $328.88M | $355.83M | $347.17M | $475.05M |
| SG&A Expenses | $336.42M | $384.78M | $325.24M | $271.43M |
| Operating Expenses | $687.68M | $805.81M | $677.43M | $741.54M |
| Total Costs & Expenses | $775.72M | $891.79M | $751.43M | $837.92M |
| Interest Income | $1.48M | $1.70M | $3.33M | $3.08M |
| Interest Expense | $21.29M | $16.78M | $23.73M | $19.008M |
| Depreciation & Amortization | $0.00 | $79.14M | $43.004M | $54.81M |
| EBITDA | -$232.73M | -$301.01M | -$236.52M | -$369.06M |
| EBITDA Ratio | -$0.45 | -$0.60 | -$0.51 | -$0.90 |
| Operating Income | -$231.03M | -$387.90M | -$284.31M | -$426.60M |
| Operating Income Ratio | -$0.44 | -$0.77 | -$0.61 | -$1.04 |
| Other Income/Expenses (Net) | -$22.99M | -$9.04M | -$6.65M | -$4.94M |
| Income Before Tax | -$254.02M | -$396.93M | -$290.97M | -$431.54M |
| Income Before Tax Ratio | -$0.49 | -$0.79 | -$0.62 | -$1.05 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$254.14M | -$396.93M | -$290.97M | -$431.54M |
| Net Income Ratio | -$0.49 | -$0.79 | -$0.62 | -$1.05 |
| EPS | -$0.47 | -$0.74 | -$0.54 | -$0.80 |
| Diluted EPS | -$0.47 | -$0.74 | -$0.54 | -$0.80 |
| Weighted Avg Shares Outstanding | $536.56M | $536.56M | $538.72M | $539.69M |
| Weighted Avg Shares Outstanding (Diluted) | $536.56M | $536.56M | $538.72M | $539.69M |
Over the last four quarters, RemeGen Co., Ltd. achieved steady financial progress, growing revenue from $411.32M in Q2 2024 to $522.30M in Q1 2025. Gross profit stayed firm with margins at 83% in Q1 2025 versus 77% in Q2 2024. Operating income totaled -$231.03M in Q1 2025, maintaining a -44% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$232.73M. Net income rose to -$254.14M, with EPS at -$0.47. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan